行情

MNKD

MNKD

曼恩凯德生物医疗
NASDAQ

实时行情|Nasdaq Last Sale

1.560
+0.050
+3.31%
盘后: 1.640 +0.08 +5.13% 19:34 02/21 EST
开盘
1.530
昨收
1.510
最高
1.690
最低
1.510
成交量
493.70万
成交额
--
52周最高
2.340
52周最低
1.020
市值
3.22亿
市盈率(TTM)
-6.0583
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MNKD价格均价为2.800,最高价位3.000,最低价为2.500。

EPS

MNKD 新闻

更多
  • MannKind announces new Afrezza data
  • seekingalpha · 1天前
  • FDA implements new rule aimed at boosting competition in insulin
  • Seeking Alpha - Article · 2天前
  • MannKind announces new Afrezza data
  • Seeking Alpha - Article · 2天前
  • MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)
  • GlobeNewswire · 2天前

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

MNKD 简况

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
展开

微牛提供MannKind Corporation(NASDAQ-MNKD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MNKD股票新闻,以帮助您做出投资决策。